-+ 0.00%
-+ 0.00%
-+ 0.00%

CNS Pharmaceuticals prices $22.5 million private placement at $2.30 per share

PUBT·05/04/2026 11:04:25
Listen to the news
CNS Pharmaceuticals prices $22.5 million private placement at $2.30 per share
  • CNS Pharmaceuticals entered securities purchase agreements for an oversubscribed private placement expected to raise about USD 22.5 million in gross proceeds.
  • Financing includes sale of 650,000 common shares at USD 2.3 per share, pre-funded warrants to buy 9,143,479 common shares at USD 2.299 per warrant.
  • Pre-funded warrants carry an exercise price of USD 0.001 per share; closing expected around May 5, 2026.
  • Proceeds earmarked for acquiring clinical-stage assets with near-term catalysts, working capital, general corporate purposes; company also pursuing out-licensing of legacy Berubicin and TPI-287 programs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202605040700ACCESSWRNAPR_____1163368) on May 04, 2026, and is solely responsible for the information contained therein.